Janssen-Cilag GmbH

Clinical trials sponsored by Janssen-Cilag GmbH, explained in plain language.

Now part of Johnson & Johnson JNJ NYSE

German subsidiary of Johnson & Johnson's pharmaceutical division, developing and marketing medicines.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1

Real-world study tracks guselkumab's impact on IBD patients

Disease control Recruiting now

This study will follow 500 people with Crohn's disease or ulcerative colitis who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission and how the treatment affects daily life, including fatigue and work productivity. The goal is to underst…

Sponsor: Janssen-Cilag G.m.b.H • Aim: Disease control

Last updated Aug 30, 2026 00:00 UTC

Janssen-Cilag GmbH

Real-world study tracks guselkumab's impact on IBD patients